Fate Therapeutics Inc (NASDAQ:FATE) to Post FY2019 Earnings of ($1.17) Per Share, Svb Leerink Forecasts

Fate Therapeutics Inc (NASDAQ:FATE) – Research analysts at Svb Leerink issued their FY2019 earnings per share estimates for shares of Fate Therapeutics in a report released on Thursday, March 28th, according to Zacks Investment Research. Svb Leerink analyst D. Graybosch expects that the biopharmaceutical company will earn ($1.17) per share for the year. Svb Leerink currently has a “Outperform” rating and a $20.00 price target on the stock. Svb Leerink also issued estimates for Fate Therapeutics’ FY2020 earnings at ($1.15) EPS, FY2021 earnings at ($1.84) EPS, FY2022 earnings at ($2.20) EPS and FY2023 earnings at ($2.27) EPS.

FATE has been the subject of several other reports. Zacks Investment Research lowered Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 7th. Stephens lowered Fate Therapeutics from an “overweight” rating to an “equal” rating in a research note on Thursday, January 3rd. BidaskClub upgraded Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. Wedbush raised their target price on Fate Therapeutics from $19.00 to $21.00 and gave the company an “outperform” rating in a research note on Monday, February 11th. Finally, Leerink Swann started coverage on Fate Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $20.00 target price for the company. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $19.63.

Fate Therapeutics stock traded down $0.10 during mid-day trading on Monday, hitting $16.84. 18,765 shares of the company were exchanged, compared to its average volume of 650,455. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.53 and a quick ratio of 7.53. Fate Therapeutics has a 1-year low of $8.35 and a 1-year high of $19.11. The firm has a market capitalization of $1.04 billion, a P/E ratio of -14.15 and a beta of 2.05.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Fate Therapeutics had a negative return on equity of 59.04% and a negative net margin of 1,405.06%.

In related news, Director Amir Nashat sold 90,000 shares of Fate Therapeutics stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $14.14, for a total value of $1,272,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Cindy Tahl sold 25,000 shares of Fate Therapeutics stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $16.15, for a total value of $403,750.00. Following the completion of the sale, the general counsel now owns 115,418 shares of the company’s stock, valued at $1,864,000.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 304,058 shares of company stock valued at $4,495,479. 23.19% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in FATE. Redmile Group LLC increased its position in Fate Therapeutics by 58.9% in the third quarter. Redmile Group LLC now owns 10,576,363 shares of the biopharmaceutical company’s stock worth $172,289,000 after purchasing an additional 3,920,401 shares during the period. BlackRock Inc. increased its position in Fate Therapeutics by 45.0% in the fourth quarter. BlackRock Inc. now owns 5,031,783 shares of the biopharmaceutical company’s stock worth $64,557,000 after purchasing an additional 1,562,252 shares during the period. Partner Fund Management L.P. acquired a new stake in Fate Therapeutics in the third quarter worth about $24,455,000. FMR LLC increased its position in Fate Therapeutics by 15.3% in the third quarter. FMR LLC now owns 7,637,402 shares of the biopharmaceutical company’s stock worth $124,413,000 after purchasing an additional 1,011,596 shares during the period. Finally, Victory Capital Management Inc. increased its position in Fate Therapeutics by 150.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,318,860 shares of the biopharmaceutical company’s stock worth $16,921,000 after purchasing an additional 791,540 shares during the period. Hedge funds and other institutional investors own 91.71% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

See Also: Swap

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.